MEETING THE STANDARDS: FDA MANDATORY RAPID INFLUENZA DETECTION TEST - - PowerPoint PPT Presentation

MEETING THE STANDARDS: FDA MANDATORY RAPID INFLUENZA DETECTION TEST (RIDTs) RECLASSIFICATION

NOVEMBER 6, 2017

SALLY A. HOJVAT M.Sc., Ph.D. Retired as Director of FDA Division of Microbiology Devices, CDRH

Learning Objectives

• Describe the FDA reclassification of rapid

immunoassay detection tests (RIDT’s) for 2018

• Discuss the reason for FDA’s implementation of

the new reclassification and how that impacts not only manufacturers but also the physician, the laboratory, and the patient

• Identify the information RIDT users must have

from manufacturers to determine whether or not their current testing meets the reclassification

TOPICS COVERED

• How does FDA evaluate in- vitro diagnostic devices (IVDs)?
• What does FDA mean by “reclassification” of an IVD test?
• Why did FDA “reclassify” rapid, influenza diagnostic tests (RIDTs)?
• Why have some rapid influenza tests become unsafe and ineffective
• ver time?
• What are the implications of “reclassification” of RIDTs for

manufacturers, distributors, physicians and clinical laboratories and POC facilities?

• Why is there continued value in use of rapid RIDT’s for influenza

detection and diagnosis of infection?

1

FDA’s Overall Mission

Get “safe and effective” diagnostic devices/systems to market as quickly as possible Ensure that diagnostic devices/systems

• n the market are

“safe and effective”

2

Reasons to Regulate in-vitro Diagnostics (IVDs)

• To ensure that IVDs are “safe and effective” for

– their intended use – by an intended user – in their intended location

• A “safe and effective” IVD should give a correct

answer consistently which can be understood by all intended users which may include….

– highly trained laboratory professionals – minimally trained healthcare workers

3

FDA’s Risk Class Based Regulation of IVDs

Class I - Low likelihood of harm Class II -Moderate likelihood of harm Class III - High or unknown likelihood

• f harm

Significant risk

“Knowledge Mitigates Risk”

Knowledge

Risk

4

Scope of FDA Reclassification Rule

Rapid Influenza Diagnostic Tests (RIDTs)

Intended Use = detect influenza virus antigens directly from clinical specimens, previously FDA classified as “influenza virus serological reagents”; now-  Reclassified from 21 CFR 866.3330, Class I to 21 CFR 866.3328, Class II with Special Controls Devices in this category are visual and reader based RIDTs. Note: Molecular rapid influenza tests are already FDA categorized as Class II devices

5

Why did FDA decide to Change the Classification of Influenza RIDT’s?

Let’s take a closer look at the public health consequences of influenza infections and the influenza virus itself that causes an infection, for the answer

6

Public Health Need for Accurate & Rapid Influenza RIDT’s

Clinical Decisions: Testing decisions = linked directly to clinical decisions related to antiviral treatment and clinical management of individual patients Surveillance: Control of suspected outbreaks: Decisions by CDC to initiate prevention /control measures for acute respiratory disease

• utbreaks of suspected influenza

7

Public Health Consequences of Influenza Infections in the U.S.

I

• Typical Season: 9-36 million infections, ~200,000

hospitalizations, and 12-50,000 deaths

• Annual Economic Burden: $52 to $199 billion in healthcare

costs, lost productivity Individual Risk Factors: Seasonal variation associated with Antigenic drift of circulating viruses; human host factors i.e. environmental, demographic, genetic, and clinical

• Emergence of novel viruses with high human-to-human

transmissibility and virulence causes epidemics and pandemics (e.g. 2009-2010 Influenza A H1N1)

8

Influenza Viruses and the Seasonality

• f Influenza Infections

Influenza virus surface proteins hemagglutinin (HA) & neuraminidase (NA). https://www.cdc.gov/flu/images.htm

• Q. Why do we need revaccination against influenza every

year with a different cocktail of influenza virus antigens?

• A. Because influenza viruses mutate continuously and

rapidly, changing their surface antigenic glycoproteins (HA and NA) genes

9

CDC Oct. 2015-Sept. 2016 = 76,293 Cases Virus Strains Circulating=Influenza AH1N1 / AH3N2 / +B’s

10

New Antigenic Drifts with Pandemic Potential

• CDC/WHO have concerns when a new subtype
• f A with a novel HA or NA emerges in a human

host from an animal population = five H7N9 Chinese epidemics since 2013, each more pathogenic

11

Reasons for Sub-optimal Performance

• f Influenza RIDT’s
• Antigenic drift / newly emerging viruses =

changed surface protein antigens . Current RIDTs may not now have the specific antibodies to recognize them

• Quality and timing of the collected specimen after

infection . 48h samples = highest viral load

• Competency of the operator to perform the test
• Quality of reagent manufacturing

12

What Type of Problems with RIDT’s were Identified by FDA?

Low Sensitivity and Failure to detect Influenza Viral Infection in devices FDA cleared since 1998: Flu A Point Estimate Ranges = Sensitivity: 73.8% (95% CI: 64.4%-81.9%) Specificity: 94.2% (95% CI: 91.0%-96.3%) Flu B Point Estimate Ranges = Sensitivity: 60.0% (95% CI: 45.2%-73.6%) Specificity: 97.8% (95% CI: 88.7%-99.6%)

• Lack of post-market monitoring to ensure tests continue to

detect newly emerging influenza virus strains

13

Clinical Decisions

Inadequate Performance as a Risk to Public Health

• False negative results: may lead to overuse
• f antibiotics and failure to institute proper

infection control procedures

• False positive results: may lead to

unnecessary use of anti-viral therapy or infection controls and may delay antibiotic treatment needed for a bacterial infection

14

Summary of FDA’s Reclassification

• f Influenza RIDTs
• Scope of Reclassification
• Reasons for Reclassification
• Special Controls
• Implementation Date
• Implications of RIDT Reclassification

for Manufacturers and Distributors; Physicians and Laboratory Facilities

15

Class I vs. Class II Requirements

Class I = current classification of RIDTs Subject to General Controls e.g.

• Registration and Listing
• Notifications of risks, repair, replacement, or refund
• Adverse event reporting

Subject to GMP’s, including Design Controls Must submit a 510(k) to FDA for a new device Class II = reclassification of RIDTs Subject to General Controls Subject to Special Controls Subject to GMPs, including Design Controls Must submit a 510(k) to FDA for a new device

16

Summary of FDA’s Reasons for Reclassification of RIDTs

• Influenza diagnostics currently regulated as Class I, do not

all meet the needs of patients, physicians, or public health

• Need to mitigate known risks associated with poor

performance of Class I RIDTs due to viral antigenic changes

• FDA believes General Controls are insufficient to

reasonably assure “safety and effectiveness” of RIDTs

• Re-classification to Class II will allow for Special Controls to

be applied to RIDTs

• Will establish and maintain minimum performance criteria for

RIDT’s throughout their product life cycle

• Promote the development of new and improved RIDTs

17

Implementation of Special Controls for Class II RIDTs: Impact on Manufacturers

• 1. Minimum clinical performance criteria requirement

demonstrated using a currently appropriate and FDA accepted comparator method.

• 2. Requirement for annual reactivity testing and results

reporting

• 3. Provision for testing in a declared emergency or potential

emergency once viral samples are available

18

Specificity All influenza detection devices should demonstrate specificity with a lower bound of the 95% CI > 90% for Flu A and Flu B Sensitivity When compared to viral culture as the reference method:

• Flu A Point Estimate = 90%; 95% CI lower bound 80%
• Flu B Pont Estimate = 80%; 95% CI lower bound 70%

When compared to a molecular comparator method:

• Flu A Point Estimate = 80%; 95% CI lower bound 70%
• Flu B Point Estimate = 80%; 95% CI lower bound 70%
• 1. Minimum Clinical Performance Criteria

& Reference/Comparator Method

19

Manufacturers of Class II RIDTs should develop a post- market test plan for annual reactivity testing with contemporary circulating viruses following a standardized

• protocol. This will enable comparability between RIDTs
• These viruses will be available each year from CDC
• 3. Also any new emerging influenza strain will be

available if a public health emergency is declared

• Testing protocol and proposed results interpretation

and presentation format will be included with the viral panels

• 2. Annual Reactivity Testing and

Result Reporting

20

CDC Analytical Panel for Mandatory Annual Testing by Manufacturers

Human Influenza Virus Panel for the 2017 annual reactivity testing may be requested from CDC at the

following website

https://www.cdc.gov/flu/dxfluviruspanel/index.htm

The 2017 Panel:

Influenza Virus Updated A(H1N1) A/Brisbane/59/2007 A/Fujian Gulou/1896/2009 A(H3N2) A/Perth/16/2009 A/Hong Kong/4801/2014* A (H1N1)pdm09 A/California/07/2009*

A/Michigan/45/2015*

B (Victoria lineage) B/Brisbane/60/2008* B/Texas/2/2013 B (Yamagata lineage) B/Wisconsin/01/2010 B/Phuket/3073/2013*

21

New Labeling Requirements for Influenza RIDTs

Testing results from the last 3 years since a device was cleared must be added to the labeling in a separate section or provided on the manufacturer’s website by July 31 of each year In the absence of reactivity, a manufacturer would need to include a limitation in the test labeling regarding reactivity with the specific strain(s) not detected by the test These labeling updates do not need to be submitted to FDA

22

What Remains Unchanged for Manufacturers?

• Compliance with GMP regulations
• 510k submission to FDA for all new RIDTs, whether

antigen or molecular, manual or reader result-based

• The requirement for all RIDTs to conduct clinical

and analytical performance studies

• A CLIA waiver submission is required if intended

use is POC

• Manufacturer’s responsibility to ensure reliable

performance throughout the device's "Total Product Life Cycle”

23

Implementation Date of the Reclassification

• Final Order effective date: February 13, 2017
• Special Controls compliance date for devices

legally marketed prior to February 13, 2017 is January 12, 2018

• Reclassification letter info. for manufacturers if

need to submit or resubmit an RIDT

– Regulation: 21 CFR 866.3328, Influenza virus antigen detection test system – Regulatory Class: Class II – Product Code: PSZ

24

Reclassification Implications for Distributors of RIDTs

• After January 12, 2018, FDA could take actions,

pursuing seizure of Influenza RIDTs held by a distributor that do not meet the Special Controls

• Although a low FDA priority ,distributors should

manage their inventory so that they only possess and distribute devices that meet the Special Controls as of the compliance date

25

RIDT Reclassification: Implications for Physicians and Laboratory Facilities

• Some currently manufactured and distributed influenza

antigen RIDTs will not achieve the new Special Controls performance criteria and will be withdrawn from the market on January 12th, 2018

• Physicians and testing facilities who still possess

Influenza antigen RIDTs that do not meet the Special Controls by January 12th can continue to use them until they expire

• When purchasing new influenza RIDTs, physicians

and laboratories should check test labeling claims and manufacturer’s websites to see if the manufacturer has conformed with reclassification Special Controls

26

Why Continue to Use Influenza Antigen RIDTs?

All antigen–based RIDTs that conform to the new FDA Special Controls reclassification requirements will continue to be valuable tools for diagnosing influenza because :

27

Reasons to Continue Using Influenza Antigen RIDTs

• Low cost ,and minimum if any equipment needed
• Can be used in low resource settings, remote rural

areas, physicians offices or outpatient clinics

• Have high positive predictive value, improved

sensitivity, short time to results contributing to appropriate treatment decisions, e.g. reducing use

• f antibiotics and timely administration of anti-virals
• Useful during influenza outbreaks when public

health labs are overwhelmed with samples for nucleic acid (RT-PCR) testing or culture

28

FDA Contact for Any Additional Questions

• Stefanie Akselrod
• Division of Microbiology Devices
• Center for Devices and Radiological Health

Food and Drug Administration

• Tel: 1-301-796-6188

Questions?